<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.0 20120330//EN" "http://jats.nlm.nih.gov/publishing/1.0/JATS-journalpublishing1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="article-commentary" dtd-version="1.0" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="issn">1043-3155</journal-id>
<journal-id journal-id-type="nlm-ta">Pediatr Neurol Briefs</journal-id>
<journal-id journal-id-type="pmc">pedneurbriefs</journal-id>
<journal-id journal-id-type="iso-abbrev">Pediatr Neurol Briefs</journal-id>
<journal-title-group>
<journal-title>Pediatric Neurology Briefs</journal-title>
<abbrev-journal-title>Pediatr Neurol Briefs</abbrev-journal-title>
</journal-title-group>
<issn pub-type="epub">2166-6482</issn>
<issn pub-type="ppub">1043-3155</issn>
<issn-l>2166-3155</issn-l>
<publisher>
<publisher-name>Pediatric Neurology Briefs Publishers</publisher-name>
<publisher-loc>Chicago, IL, USA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">PNB-10-65</article-id>
<article-id pub-id-type="doi">10.15844/pedneurbriefs-10-9-1</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Attention Deficit Disorders</subject>
</subj-group>
<subj-group subj-group-type="Discipline-v2">
<subject>Neurology</subject>
<subject>Pediatrics</subject>
<subject>Nervous System Diseases</subject>
<subject>Child Development</subject>
<subject>Brain Diseases</subject>
<subject>Neurosurgery</subject>
<subject>Child</subject>
<subject>Infant</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Usage of CNS Stimulants by Pediatric Neurologists</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-0173-7931</contrib-id>
<name>
<surname>Millichap</surname>
<given-names>J. Gordon</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="AF0001">1</xref>
<xref ref-type="aff" rid="AF0002">2</xref>
<xref ref-type="corresp" rid="cor1">&#x002A;</xref>
</contrib>
</contrib-group>
<aff id="AF0001">
<label>1</label>Division of Neurology, Children&#x0027;s Memorial Hospital, Chicago, IL</aff>
<aff id="AF0002">
<label>2</label>Departments of Pediatrics and Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL</aff>
<author-notes>
<corresp id="cor1"><label>&#x002A;</label>Correspondence: Dr. J. Gordon Millichap, E-mail: <email xlink:href="jgmillichap@northwestern.edu">jgmillichap@northwestern.edu</email>
</corresp>
</author-notes>
<pub-date date-type="pub" publication-format="print">
<month>09</month>
<year>1996</year>
</pub-date>
<pub-date date-type="pub" publication-format="electronic">
<day>01</day>
<month>06</month>
<year>2016</year>
</pub-date>
<volume>10</volume>
<issue>9</issue>
<fpage>65</fpage>
<lpage>66</lpage>
<permissions>
<copyright-statement>Copyright: &#x00A9; 1996 The Author(s)</copyright-statement>
<copyright-year>1996</copyright-year>
<license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/">
<license-p>This work is licensed under the <uri xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution 4.0 International License</uri>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
</license>
</permissions>
<related-article id="R1" related-article-type="commentary-article">
<article-title>Usage of CNS stimulants for ADHD by pediatric neurologists. A questionnaire survey</article-title>
</related-article>
<abstract abstract-type="web-summary" specific-use="electronic-only">
<p>An overuse of methylphenidate (MPH) in the treatment of attention deficit disorders (ADHD) has been reported by the International Narcotics Control Board, and the potential for drug abuse has prompted media criticism and cause for concern among some parents and physicians.</p>
</abstract>
<kwd-group>
<kwd>Methylphenidate</kwd>
<kwd>Attention Deficit Disorders</kwd>
<kwd>Stimulant Medications</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<p>An overuse of methylphenidate (MPH) in the treatment of attention deficit disorders (ADHD) has been reported by the International Narcotics Control Board, and the potential for drug abuse has prompted media criticism and cause for concern among some parents and physicians. A questionnaire was mailed to 160 pediatric neurologists and clinic directors in the United States, and 53 (33%) located in 28 different States responded. A diagnosis of ADHD was made in &#x003C;5 to 100% (mean 33%) of patients treated, and 10 to 96% (mean 51%) of ADHD patients received stimulant medications. The age groups of patients receiving MPH were 3-5 years (8.7%), 6-12 years (70.3%), 13-18 years (20.4%), and adults (0.6%). The drug of choice was MPH (90%). Pemoline and dextroamphetamine were equally favored as 2nd or 3rd choice stimulants. The mean average daily dose of MPH was 20 mg (range 10-40 mg); the mean maximum daily dose was 52 mg (range 25-85 mg). Drug holidays at weekends and school vacations were recommended by 65%. The duration of therapy with stimulants ranged from 1 to 5 years (mean 3.5 years). The adverse effects of MPH were as follows: personality changes in 7%, tics (5%), weight loss (4%), seizures (0.9%), and miscellaneous (2.3%), including insomnia (3), headache (2), increased activity (2), and parental anxiety (1). [<xref ref-type="bibr" rid="CIT0001">1</xref>]</p>
<p>COMMENT. An overuse of methylphenidate by physicians treating attention deficit hyperactivity disorders in the United States was not supported by this questionnaire survey of pediatric neurologists. The side effects reported, especially personality changes, are usually dose related.</p>
<p>Contraindications or factors requiring extra caution in the use of stimulants for ADHD are as follows: 1) Tourette&#x2019;s syndrome or tics, 2) family history of tics, 3) history of seizures and/or EEG dysrhythmia, 4) history of drug abuse/dependence, 5) family history of drug abuse, 6) psychosis or anxiety/depression, 7) poor nutrition or short stature, 8) headaches, sleep disturbance, 9) liver dysfunction (pemoline), 10) treatment with other medications eg. clonidine, MAO inhibitors.</p>
</body>
<back>
<ref-list>
<ref id="CIT0001">
<label>1</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Millichap</surname>
<given-names>JG</given-names>
</name>
</person-group>
<article-title>Usage of CNS stimulants for ADHD by pediatric neurologists. A questionnaire survey</article-title>
<source>Ped Neur Briefs</source>
<year>1996</year>
<month>Sept</month>
<volume>10</volume>
<fpage>65</fpage>
</element-citation>
</ref>
</ref-list>
</back>
</article>
